Pharmacogenomics will help explain why drugs work better in some patients than in others. These tools should be used as early in the drug development process as possible.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Pharmaceutical Researchers and Manufacturers of America.
Poirer,J. et al. 1995. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's disease. Proc. Natl. Acad. Sci. USA 92: 12260–12264.
Farlow, M.R. et al. 1996. Apolipoprotein E genotype and gender influence response to tacrine therapy. Ann. NY Acad. Sci. 802: 101–110.
Richard, F. et al. 1997. APOE genotyping and response to drug treatment in Alzheimer's disease. Lancet 349: 539.
Department of Health and Human Services. 1997. Guidance for Industry: Drug Metabolism/Drug Interaction Studies in the Drug Development Process: Studies in Vitro. FDA, Rockville, MD.
Rights and permissions
About this article
Cite this article
Marshall, A. Getting the right drug into the right patient. Nat Biotechnol 15, 1249–1252 (1997). https://doi.org/10.1038/nbt1197-1249
Issue Date:
DOI: https://doi.org/10.1038/nbt1197-1249
This article is cited by
-
Why pharmacogenomics? Why now?
Nature Biotechnology (1998)